Sustaining short-term gains for future progress

International Clinical Psychopharmacology

Volumn 16, Issue SUPPL. 1, 2001, Pages

  Canas F ^a  

^a Hospital Psiquiatrico de Madrid   (Spain)

Author keywords

Acute psychosis; Antipsychotics; Intramuscular formulation; Ziprasidone

Indexed keywords

NEUROLEPTIC AGENT; ZIPRASIDONE;

ACUTE PSYCHOSIS; CONFERENCE PAPER; DRUG MECHANISM; DRUG TOLERABILITY; EMERGENCY HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; RATING SCALE; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY;

EID: 0035112944     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200101001-00003     Document Type: Conference Paper

References (34)

1. Contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms
2. The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute, non-organic psychosis
3. The relationship of pharmacology to side effects
4. An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone
5. Ziprasidone
6. Neuroleptic withdrawal in schizophrenic patients: A review of the literature
7. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures
8. Sedation in acute and chronic agitation
9. The positive and negative syndrome scale (PANSS) for schizophrenia
10. Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: Population pharmacokinetic modeling
11. Clinical Global Impression scale
12. Clinical characteristics, health beliefs and compliance with maintenance treatment: A comparison between regular and irregular attenders at a depot clinic
13. Ziprasidone metabolism and cytochrome P450
14. A comparison of rapid-acting, intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation
15. Rapid-acting intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation
16. Current concepts in the pharmacotherapy of acute psychosis
17. The identification and management of drug-induced akathisia
18. Phenomenology and treatment of agitation
19. Common treatment goals of antipsychotics: Acute treatment
20. The evaluation and treatment of first-episode psychosis
21. Antipsychotic polypharmacy, part 1: Therapeutic option or dirty little secret?
22. Validation of the Behavioural Activity Rating Scale (BARS)™: A novel measure of activity in agitated patients
23. A comparison of fixed-dose intramuscular (IM) ziprasidone with flexible-dose IM haloperidol
24. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
25. The population pharmacokinetics of intramuscular ziprasidone in healthy volunteers and schizophrenic patients
26. Why do schizophrenic patients refuse to take their drugs?
27. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: Methodological concerns
28. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal
29. Anchoring the BPRS to improved reliability
30. Treatment of agitation and aggression